mothertobaby semaglutide pregnancy fact sheet 2024 and mothertobaby tirzepatide pregnancy fact sheet

Outcomes and assessments Results for the primary and secondary outcomes were published 19

Data from the SURPASS-4 trial indicated that patients using Tirzepatide experienced a significantly slower decline in eGFR compared to those on insulin glargine

Its unclear whether this will result in more states covering these products

Dr Kosiborod has served as a consultant or as an advisory board member for 35Pharma, Alnylam, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Dexcom, Eli Lilly, Esperion Therapeutics, Janssen, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pfizer, Pharmacosmos, scPharmaceuticals, Structure Therapeutics, Vifor Pharma, and Youngene Therapeutics